---
title: "Zelgen: The Phase III clinical trial of Hydrochloride Gikaxitin Tablets for the treatment of active ankylosing spondylitis has reached the primary efficacy endpoint"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/261835827.md"
description: "Zelgen announced that its self-developed Jikaxitinib hydrochloride tablets achieved the primary efficacy endpoint in the Phase III clinical trial for the treatment of active ankylosing spondylitis, with statistical significance (p"
datetime: "2025-10-20T08:34:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/261835827.md)
  - [en](https://longbridge.com/en/news/261835827.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/261835827.md)
---

# Zelgen: The Phase III clinical trial of Hydrochloride Gikaxitin Tablets for the treatment of active ankylosing spondylitis has reached the primary efficacy endpoint

According to the Zhitong Finance APP, Zelgen (688266.SH) announced that its self-developed Class 1 new drug, Hydrochloride Jikaxitinib Tablets (formerly known as Hydrochloride Jakatinib Tablets), has achieved the primary efficacy endpoint with statistical significance (p<0.0001) in the Phase III clinical trial titled "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Hydrochloride Jakatinib Tablets for the Treatment of Patients with Active Ankylosing Spondylitis" (Protocol Number: ZGJAK029). The company will accelerate the process of bringing Hydrochloride Jikaxitinib Tablets to market for the treatment of patients with active ankylosing spondylitis

### Related Stocks

- [688266.CN](https://longbridge.com/en/quote/688266.CN.md)

## Related News & Research

- [Just 4% of fund managers see a hard landing - BofA survey](https://longbridge.com/en/news/286866256.md)
- [Is RFK Jr.'s 'carnivore diet' healthy? Here's what you need to know.](https://longbridge.com/en/news/287079002.md)
- [There May Be Some Bright Spots In Sudarshan Colorants India's (NSE:SUDARCOLOR) Earnings](https://longbridge.com/en/news/287134327.md)
- [05:20 ETThrough the America's Most Artistic Kid Competition, Colossal Raises $1.6 Million While Celebrating the Next Gen of Creative Visionaries](https://longbridge.com/en/news/287037755.md)
- [Investors Can Find Comfort In Polaris Media's (OB:POL) Earnings Quality](https://longbridge.com/en/news/287004804.md)